Multi-modality as a new pharmacological approach for treatment of depression: The role of vortioxetine

F. Caraci, G. Di Sciascio

Research output: Contribution to journalArticle

Abstract

Recent evidence, such as that from the STAR-D study, have demonstrated that several unmet needs are still present in the treatment of major depression. The "classical" approach adopted to develop new antidepressants drugs, based on selectivity, did not result in increased remission rates in clinical practice, whereas multi-modality represents a new approach to develop novel antidepressants endowed with multiple actions that affect several pharmacological targets. Multimodal antidepressants, developed in the last three years, act through at least two pharmacological modes of action (serotonin reuptake inhibition, agonist/antagonists on neurotransmitter receptors) on at least two or more pharmacologic targets. Vortioxetine is a novel multimodal antidepressant that exerts its antidepressant efficacy in animal models of depression through a combination of two pharmacological modes of action: reuptake inhibition and receptor activity. In vitro studies indicate that vortioxetine is antagonist of 5-HT3, 5-HT7 and 5-HT1D receptors, a partial agonist of 5-HT1B receptors, an agonist of 5-HT1A receptors, and inhibitor of the serotonin transporter. The combination of 5-HT1A agonism with 5-HT3 antagonism can explain the rapid 5-HT cell firing induced by vortioxetine compared to SSRIs such as fluoxetine. Vortioxetine is also able to activate the glutamatergic system in the rat frontal cortex through antagonism at 5-HT3, 5-HT7 receptors. All these pharmacological modes of action can contribute to explain the increased clinical efficacy of vortioxetine in the treatment of cognitive symptoms of depression. Cognitive deficits in depression are often associated with both a suboptimal response to antidepressants and reduced remission rates. Vortioxetine is the first multimodal antidepressant available for the treatment of depression with a specific, positive impact on cognitive symptoms.

Original languageEnglish
Pages (from-to)210-223
Number of pages14
JournalItalian Journal of Psychopathology
Volume21
Issue number2
Publication statusPublished - Jun 1 2015

Fingerprint

Antidepressive Agents
Pharmacology
Depression
Neurobehavioral Manifestations
Serotonin
Receptor, Serotonin, 5-HT1D
Receptor, Serotonin, 5-HT1B
Serotonin 5-HT1 Receptor Agonists
Serotonin 5-HT3 Receptor Antagonists
Serotonin Plasma Membrane Transport Proteins
Neurotransmitter Receptor
Receptor, Serotonin, 5-HT1A
Fluoxetine
Frontal Lobe
vortioxetine
Animal Models

Keywords

  • Cognitive symptoms
  • Depression
  • Glutamatergic System
  • Multi-modality
  • Serotonin
  • Vortioxetine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Multi-modality as a new pharmacological approach for treatment of depression : The role of vortioxetine. / Caraci, F.; Di Sciascio, G.

In: Italian Journal of Psychopathology, Vol. 21, No. 2, 01.06.2015, p. 210-223.

Research output: Contribution to journalArticle

@article{5d2f543a30b245e18b5d82f7e49032e5,
title = "Multi-modality as a new pharmacological approach for treatment of depression: The role of vortioxetine",
abstract = "Recent evidence, such as that from the STAR-D study, have demonstrated that several unmet needs are still present in the treatment of major depression. The {"}classical{"} approach adopted to develop new antidepressants drugs, based on selectivity, did not result in increased remission rates in clinical practice, whereas multi-modality represents a new approach to develop novel antidepressants endowed with multiple actions that affect several pharmacological targets. Multimodal antidepressants, developed in the last three years, act through at least two pharmacological modes of action (serotonin reuptake inhibition, agonist/antagonists on neurotransmitter receptors) on at least two or more pharmacologic targets. Vortioxetine is a novel multimodal antidepressant that exerts its antidepressant efficacy in animal models of depression through a combination of two pharmacological modes of action: reuptake inhibition and receptor activity. In vitro studies indicate that vortioxetine is antagonist of 5-HT3, 5-HT7 and 5-HT1D receptors, a partial agonist of 5-HT1B receptors, an agonist of 5-HT1A receptors, and inhibitor of the serotonin transporter. The combination of 5-HT1A agonism with 5-HT3 antagonism can explain the rapid 5-HT cell firing induced by vortioxetine compared to SSRIs such as fluoxetine. Vortioxetine is also able to activate the glutamatergic system in the rat frontal cortex through antagonism at 5-HT3, 5-HT7 receptors. All these pharmacological modes of action can contribute to explain the increased clinical efficacy of vortioxetine in the treatment of cognitive symptoms of depression. Cognitive deficits in depression are often associated with both a suboptimal response to antidepressants and reduced remission rates. Vortioxetine is the first multimodal antidepressant available for the treatment of depression with a specific, positive impact on cognitive symptoms.",
keywords = "Cognitive symptoms, Depression, Glutamatergic System, Multi-modality, Serotonin, Vortioxetine",
author = "F. Caraci and {Di Sciascio}, G.",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "21",
pages = "210--223",
journal = "Giornale Italiano di Psicopatologia",
issn = "1592-1107",
publisher = "Pacini Editore s.r.l.",
number = "2",

}

TY - JOUR

T1 - Multi-modality as a new pharmacological approach for treatment of depression

T2 - The role of vortioxetine

AU - Caraci, F.

AU - Di Sciascio, G.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Recent evidence, such as that from the STAR-D study, have demonstrated that several unmet needs are still present in the treatment of major depression. The "classical" approach adopted to develop new antidepressants drugs, based on selectivity, did not result in increased remission rates in clinical practice, whereas multi-modality represents a new approach to develop novel antidepressants endowed with multiple actions that affect several pharmacological targets. Multimodal antidepressants, developed in the last three years, act through at least two pharmacological modes of action (serotonin reuptake inhibition, agonist/antagonists on neurotransmitter receptors) on at least two or more pharmacologic targets. Vortioxetine is a novel multimodal antidepressant that exerts its antidepressant efficacy in animal models of depression through a combination of two pharmacological modes of action: reuptake inhibition and receptor activity. In vitro studies indicate that vortioxetine is antagonist of 5-HT3, 5-HT7 and 5-HT1D receptors, a partial agonist of 5-HT1B receptors, an agonist of 5-HT1A receptors, and inhibitor of the serotonin transporter. The combination of 5-HT1A agonism with 5-HT3 antagonism can explain the rapid 5-HT cell firing induced by vortioxetine compared to SSRIs such as fluoxetine. Vortioxetine is also able to activate the glutamatergic system in the rat frontal cortex through antagonism at 5-HT3, 5-HT7 receptors. All these pharmacological modes of action can contribute to explain the increased clinical efficacy of vortioxetine in the treatment of cognitive symptoms of depression. Cognitive deficits in depression are often associated with both a suboptimal response to antidepressants and reduced remission rates. Vortioxetine is the first multimodal antidepressant available for the treatment of depression with a specific, positive impact on cognitive symptoms.

AB - Recent evidence, such as that from the STAR-D study, have demonstrated that several unmet needs are still present in the treatment of major depression. The "classical" approach adopted to develop new antidepressants drugs, based on selectivity, did not result in increased remission rates in clinical practice, whereas multi-modality represents a new approach to develop novel antidepressants endowed with multiple actions that affect several pharmacological targets. Multimodal antidepressants, developed in the last three years, act through at least two pharmacological modes of action (serotonin reuptake inhibition, agonist/antagonists on neurotransmitter receptors) on at least two or more pharmacologic targets. Vortioxetine is a novel multimodal antidepressant that exerts its antidepressant efficacy in animal models of depression through a combination of two pharmacological modes of action: reuptake inhibition and receptor activity. In vitro studies indicate that vortioxetine is antagonist of 5-HT3, 5-HT7 and 5-HT1D receptors, a partial agonist of 5-HT1B receptors, an agonist of 5-HT1A receptors, and inhibitor of the serotonin transporter. The combination of 5-HT1A agonism with 5-HT3 antagonism can explain the rapid 5-HT cell firing induced by vortioxetine compared to SSRIs such as fluoxetine. Vortioxetine is also able to activate the glutamatergic system in the rat frontal cortex through antagonism at 5-HT3, 5-HT7 receptors. All these pharmacological modes of action can contribute to explain the increased clinical efficacy of vortioxetine in the treatment of cognitive symptoms of depression. Cognitive deficits in depression are often associated with both a suboptimal response to antidepressants and reduced remission rates. Vortioxetine is the first multimodal antidepressant available for the treatment of depression with a specific, positive impact on cognitive symptoms.

KW - Cognitive symptoms

KW - Depression

KW - Glutamatergic System

KW - Multi-modality

KW - Serotonin

KW - Vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=84946099273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946099273&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84946099273

VL - 21

SP - 210

EP - 223

JO - Giornale Italiano di Psicopatologia

JF - Giornale Italiano di Psicopatologia

SN - 1592-1107

IS - 2

ER -